Misplaced Pages

Aderbasib

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Aderbasib
Skeletal formula of aderbasib
Clinical data
Routes of
administration		Oral
ATC code
  • None
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • methyl (6S,7S)-7-(hydroxycarbamoyl)-6--5-azaspirooctane-5-carboxylate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H28N4O5
Molar mass416.478 g·mol
3D model (JSmol)
SMILES
  • COC(=O)N1CC2(CC2)C(1C(=O)N3CCN(CC3)C4=CC=CC=C4)C(=O)NO
InChI
  • InChI=1S/C21H28N4O5/c1-30-20(28)25-14-21(7-8-21)13-16(18(26)22-29)17(25)19(27)24-11-9-23(10-12-24)15-5-3-2-4-6-15/h2-6,16-17,29H,7-14H2,1H3,(H,22,26)/t16-,17-/m0/s1
  • Key:DJXMSZSZEIKLQZ-IRXDYDNUSA-N

Aderbasib (codenamed INCB7839) is a sheddase inhibitor that may suppress tumor cell proliferation. Acting on multiple receptor classes and subclasses, aderbasib is observed to regulate the tumor necrosis factor of cancer cells. Aderbasib was being developed by Incyte as a potential adjunctive treatment for metastatic breast cancer. Development was halted in 2011 after positive findings from Phase II trials were contradicted by further research.

References

  1. "STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL" (PDF). Ama-assn.org. Retrieved 2012-10-13.
  2. "Aderbasib | CAS#791828-58-5". MedKoo. Retrieved 2012-10-13.
  3. Incyte (2011-09-19). "UBS 2011 Global Life Sciences Conference". Retrieved 2013-02-13.
  4. "Incyte Reports Third Quarter 2011 Financial Results And Provides Update On Key Clinical Programs" (Press release). BusinessWire. 2011-10-27. Retrieved 2013-02-13.

External links


Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: